TROG 04.01 - Cavilon Breast - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

Prof Paul Keall, Image X Director and VITaL trial chief investigator

15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative

TROG 04.01 – Cavilon Breast

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

Trial data-sharing made easier with HeSANDA initiative